水飛薊提取物 
英文名稱：Milk Thistle Extract 
CAS: 84604-20-6 
分子式: C25H22O10 
分子量: 482.4388 
植物來源: 菊科水飛薊屬植物水飛薊Silybum marianum （L.） Gaertn.[Carduus marianus L.]，的全草及瘦果。以瘦果入藥。 
有效成分:水飛薊中的主要有效成分是黃酮類物質,包括:水飛薊賓(Silybinin) A、B、水飛薊寧(Silydianin)、水飛薊亭(Silychristin)、Dehydrosilybinin、Isosilybinin A、B等,總稱為水飛薊素(silymarin) 
檢測方法：HPLC UV 
產品規格：水飛薊素 ≥80.0%（HPLC） 
產品性狀：淡黃色粉末 
產品用途： 
1. 保肝作用 
水飛薊素為保肝的主要活性成分, 具有再生作用, 可刺激新的肝細胞形成, 改善肝功能; 同時具有肝細胞膜保護作用, 預防細胞毒素浸潤肝細胞, 並提高膜結構缺損的恢復能力。 
用於肝炎，尚可用於治療肝硬化，脂肪肝，酒精引起的肝損害，代謝中毒性肝損傷、膽結石和脾臟病等 
2. 抗氧化 
水飛薊素的酚羥基提供氫原子而有強大的抗氧化作用。它們具有清除自由基特性,抗脂質過氧化活性。 
3. 降血脂 
水飛薊賓能抑製成年大鼠心肌細胞質膜Ca2+通道, 抑制食物誘導的血膽固醇過高,降低極低密度脂蛋白 (VLDL) 與低密度脂蛋白 (LDL), 升高高密度脂蛋白 (HDL), 可用於心血管系統疾病的治療。 
【臨床功效】 
水飛薊提取物主要用於病毒性肝炎、急慢性肝炎、肝硬化、高脂肪肝、營養代謝性疾病和心血管疾病。 
包裝規格：25公斤/紙板桶或根據客戶需要定製包裝 
保質期：24個月

產品詳詢:13657416805

參考文獻：

1. 1. 

   Lazo M, Hernaez R, Eberhardt MS, et al. Prevalence of nonalcoholic fatty liver disease in the United States. The Third National Health and Nutrition Examination Survey, 1988–1994. Am J Epidemiol. 2013;178:38–45.

2. 2. 

   Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–23.

3. 3. 

   Abenavoli L, Aviello G, Capasso R, Milic N, Capasso F. Milk thistle for treatment of nonalcoholic fatty liver disease. Hepat Mon. 2011;11:173–7.

4. 4. 

   Pasumarthy L, Srour J. Nonalcoholic steatohepatitis: a review of the literature and updates in management. South Med J. 2010;103:547–50.

5. 5. 

   Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. AM J Gastroenterol. 2003;98:960–7.

6. 6. 

   Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–73.

7. 7. 

   Burczynski FJ, Wang G, Nguyen D, Chen Y, Smith HJ, Gong Y. Silymarin and hepatoprotection. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2012;37:6–10.

8. 8. 

   Li CC, Hsiang CY, Wu SL, Ho TY. Identification of novel mechanisms of silymarin on the carbon tetrachloride-induced liver fibrosis in mice by nuclear factor-κB bioluminescent imaging-guided transcriptomic analysis. Food Chem Toxicol. 2012;50:1568–75.

9. 9. 

   George J, Pera N, Phung N, Leclercq I, Yun Hou J, Farrell G. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol. 2003;39:756–64.

10. 10. 

    Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332:1519–23.

11. 11. 

    Kwon DY, Ahn CW, Choi YJ, Kim YC. Induction of hepatic glutathione synthesis via alterations in sulfur amino acid metabolism in mice treated with silymarin acutely. FASEB J. 2013;27(805):1.

12. 12. 

    Dehmlow C, Erhard J, de Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology. 1996;23:749–54.

13. 13. 

    Lieber CS, Leo MA, Cao Q, Ren C, DeCarli LM. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol. 2003;37:336–9.

14. 14. 

    Kim M, Yang S-G, Kim JM, Lee J-W, Kim YS, Lee JI. Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: analysis of isolated hepatic stellate cells. Int J Mol Med. 2012;30:473–9.

15. 15. 

    Reddy KR, Belle SH, Fried MW, Afdhal N, Navarro VJ, Hawke RL. Rationale, challenges, and participants in a phase II trial of a botanical product for chronic hepatitis C. Clin Trials. 2012;9:102–12.

16. 16. 

    Salmi HA, Sarna S. Effect of silymarin on chemical, functional, and morphological alterations of the liver. A double-blind controlled study. Scand J Gastroenterol. 1982;17:517–21.

17. 17. 

    Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol. 1989;9:105–13.

18. 18. 

    Feher J, Deak G, Muzes G, et al. Hepatoprotective activity of silymarin (Legalon) therapy in patients with chronic liver disease. Orv Hetil. 1989;130:2723–7.

19. 19. 

    Müzes G, Deák G, Láng I, Nékám K, Niederland V, Fehér J. Effect of silimarin (Legalon) therapy on the antioxidant defense mechanism and lipid peroxidation in alcoholic liver disease (double blind protocol). Orv Hetil. 1990;22;131:863–6. Hungarian.

20. 20. 

    Velussi M, Cernigoi AM, De Monte A, Dapas F, Caffau C, Zilli M. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol. 1997;26:871–9.

21. 21. 

    Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61:2035–63.

22. 22. 

    Lucena MI, Andrade RJ, de la Cruz JP, Rodriguez-Mendizabal M, Blanco E, Sánchez-de la Cuesta F. Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study. Int J Clin Pharmacol Ther. 2002;40:2–8.

23. 23. 

    Lirussi F, Okolicsanyi L. Cytoprotection in the nineties: experience with ursodeoxycholic acid and silymarin in chronic liver disease. Acta Physiol Hung. 1992;80:363–7.

24. 24. 

    Buturova LI, Tsybizova TA, Kalinin AV. Use of Legalon in non-alcoholic fatty liver disease [in Russian]. Eksp Klin Gastroenterol. 2010;5:69–75.

25. 25. 

    Fujii M, Shibazaki Y, Wakamatsu K, et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med Mol Morphol. 2013;46:141–52.

26. 26. 

    Kleiner DE, Brunt EM, Van Natta M, Nonalcoholic Steatohepatitis Clinical Research Network, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.

27. 27. 

    Klein T, Fujii M, Sandel J, et al. Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis. Med Mol Morphol. 2013 [Epub ahead of print] PubMed PMID: 24048504.

28. 28. 

    Traber PG, Zomer E. Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS One. 2013;8:e83481.

29. 29. 

    Kawai D, Takaki A, Nakatsuka A, et al. Hydrogen-rich water prevents progression of nonalcoholic steatohepatitis and accompanying hepatocarcinogenesis in mice. Hepatology. 2012;56:912–21.

30. 30. 

    Cynis H, Kehlen A, Haegele M, et al. Inhibition of glutaminyl cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice. Int J Exp Pathol. 2013;94:217–25.

31. 31. 

    Nobili V, Svegliati-Baroni G, Alisi A, Miele L, Valenti L, Vajro P. A 360-degree overview of paediatric NAFLD: recent insights. J Hepatol. 2013;58:1218–29.

32. 32. 

    Huseini HF, Larijani B, Heshmat R, et al. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytother Res. 2006;20:1036–9.

33. 33. 

    Hussain SA. Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes. J Med Food. 2007;10:543–7.

34. 34. 

    Yao J, Zhi M, Gao X, Hu P, Li C, Yang X. Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver. Braz J Med Biol Res. 2013;46:270–7.

35. 35. 

    Trappoliere M, Caligiuri A, Schmid M, et al. Silybin, a component of silymarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol. 2009;50:1102–11.